RxDoctor Payments Data

Sheremet Gashi, MD

Internal Medicine · North Arlington, NJNPI 1114093564

Payments from drug & device makers

$470in general payments, 2019–2025

Across 24 payments — averaging $19.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exact Sciences$224
  • Novo Nordisk$105
  • Boehringer Ingelheim$43
  • Amarin Pharma, Inc.$38
  • Althera Pharmaceuticals LLC$31
  • AstraZeneca$29

What the payments were for

  • Food & beverage$470100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Exact Sciences8$224
Novo Nordisk6$105
Boehringer Ingelheim3$43
Amarin Pharma, Inc.3$38
Althera Pharmaceuticals LLC2$31
AstraZeneca2$29

How this compares

$470 in reported general payments places this provider in the 55th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$76,858
Medicare patients
200
Services billed
1,014

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide104$105,049
MounjaroTirzepatide64$73,481
EliquisApixaban67$60,422
JanuviaSitagliptin Phosphate52$37,076
JardianceEmpagliflozin35$30,324
XareltoRivaroxaban24$21,160
JanumetSitagliptin Phos/Metformin Hcl23$14,114
Breo ElliptaFluticasone/Vilanterol32$12,597
FarxigaDapagliflozin Propanediol14$11,009
Spiriva RespimatTiotropium Bromide11$9,095
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$7,311
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog13$6,163
Lantus SolostarInsulin Glargine,hum.Rec.Anlog31$4,577
Albuterol Sulfate HfaAlbuterol Sulfate151$4,299
Rosuvastatin Calcium193$3,611

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$105$105,049104 claims
Boehringer IngelheimJardiance, Spiriva Respimat$43$39,41946 claims
AstraZenecaFarxiga$29$11,00914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in North Arlington

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →